Michael Caligiuri

The role of STAT1 in viral sensitization to LPS.

BAALC, a novel marker of human hematopoietic progenitor cells.

A quantitative neuromotor predictor of antidepressant non-response in patients with major depression.

A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes.

Rituximab: converging mechanisms of action in non-Hodgkin's lymphoma?

EBV kidney allograft infection: possible relationship with a peri-graft localization of PTLD.

NK cell and DC interactions.

Loss of C/EBP alpha and favorable prognosis of acute myeloid leukemias: a biological paradox.

Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia.

Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes.

Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.

A functional magnetic resonance imaging study of cortical asymmetry in bipolar disorder.

Clinical rating scales and instruments: how do they compare in assessing abnormal, involuntary movements?

Association of diabetes with dyskinesia in older psychosis patients.

AIDS-associated malignancies.

Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease.

Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.

Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma.

Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.

A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies.

Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies.

IFN-gamma gene polymorphisms associate with development of EBV+ lymphoproliferative disease in hu PBL-SCID mice.

Functional brain asymmetries during visuomotor tracking.

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.

Failed adoptive immunotherapy with tumor-specific T cells: reversal with low-dose interleukin 15 but not low-dose interleukin 2.

Immunotherapeutic approaches for hematologic malignancies.

Differential expression of SHIP1 in CD56bright and CD56dim NK cells provides a molecular basis for distinct functional responses to monokine costimulation.

Acute myeloid leukemia with deletion 9q within a noncomplex karyotype is associated with CEBPA loss-of-function mutations.

Efficient infection of human natural killer cells with an EBV/retroviral hybrid vector.

Interleukin-2, interleukin-15, and their roles in human natural killer cells.

Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia.

The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.

A human CD34(+) subset resides in lymph nodes and differentiates into CD56bright natural killer cells.

Relationship of neuromotor disturbances to psychosis symptoms in first-episode neuroleptic-naive schizophrenia patients.

Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia.

IL-15 but not IL-2 rapidly induces lethal xenogeneic graft-versus-host disease.

Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.

Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.

Do preclinical findings of methamphetamine-induced motor abnormalities translate to an observable clinical phenotype?

Lateralized cognitive dysfunction and psychotic symptoms in schizophrenia.

The BRG1- and hBRM-associated factor BAF57 induces apoptosis by stimulating expression of the cylindromatosis tumor suppressor gene.

Src homology 2-containing inositol 5'-phosphatase 1 negatively regulates IFN-gamma production by natural killer cells stimulated with antibody-coated tumor cells and interleukin-12.

Cytokine therapy for cancer: antigen presentation.

Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.

The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.

A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation.

EBV-encoded dUTPase induces immune dysregulation: Implications for the pathophysiology of EBV-associated disease.

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.

Human natural killer cell development and biology.

Responsiveness of naive CD4 T cells to polarizing cytokine determines the ratio of Th1 and Th2 cell differentiation.

Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines.

STAT-1-mediated repression of monocyte interleukin-10 gene expression in vivo.

Striatopallidal regulation of affect in bipolar disorder.

Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology.

Autologous immune strategies to reduce the risk of leukemic relapse: consideration for IL-15.

FcgammaR-induced production of superoxide and inflammatory cytokines is differentially regulated by SHIP through its influence on PI3K and/or Ras/Erk pathways.

Tumor growth impedes natural-killer-cell maturation in the bone marrow.

Recent advances in the treatment of transplant-related lymphoma.

Evidence for discrete stages of human natural killer cell differentiation in vivo.

Immunologic approaches to acute leukemia in the elderly.

Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients.

Quantitative measurement of handwriting in the assessment of drug-induced parkinsonism.

Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study.

Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells.

Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35.

Cancer and leukemia group B leukemia correlative science committee: major accomplishments and future directions.

Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity.

A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.

Impaired hemispheric communication in schizophrenia: a study using the consonant-vowel-consonant task.

PhenoChipping of psychotic disorders: a novel approach for deconstructing and quantitating psychiatric phenotypes.

The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry.

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.

Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses.

Abnormalities in motor physiology in bipolar disorder.

Mll partial tandem duplication induces aberrant Hox expression in vivo via specific epigenetic alterations.

Human natural killer cell development.

Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells.

Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.

A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.

Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

Internal versus external: oral-motor performance as a function of attentional focus.

Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity.

Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.

High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia.

Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.

Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.

Chronic lymphocytosis of functionally immature natural killer cells.

Transcriptional control of human T-BET expression: the role of Sp1.

FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

The PP2A inhibitor SET regulates natural killer cell IFN-gamma production.

Specific tumor suppressor function for E2F2 in Myc-induced T cell lymphomagenesis.

Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis.

FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications.

SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.

Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia.

Colocalization of the IL-12 receptor and FcgammaRIIIa to natural killer cell lipid rafts leads to activation of ERK and enhanced production of interferon-gamma.

IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro.

Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia.

A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.

Isolation and characterization of human natural killer cell subsets.

MicroRNA expression in cytogenetically normal acute myeloid leukemia.

Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720.

The Mll partial tandem duplication: differential, tissue-specific activity in the presence or absence of the wild-type allele.

Human natural killer cells.

TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells.

Natural killer cells in innate immunity and cancer.

Tumor growth decreases NK and B cells as well as common lymphoid progenitor.

Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.

The Axl/Gas6 pathway is required for optimal cytokine signaling during human natural killer cell development.

A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab.

Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells.

The humanized CD40 antibody SGN-40 demonstrates pre-clinical activity that is enhanced by lenalidomide in chronic lymphocytic leukaemia.

Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22.

TSC-22 contributes to hematopoietic precursor cell proliferation and repopulation and is epigenetically silenced in large granular lymphocyte leukemia.

Reformed consent: adapting to new media and research participant preferences.

Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells.

A novel mouse model for the aggressive variant of NK cell and T cell large granular lymphocyte leukemia.

Handwriting movement analyses for monitoring drug-induced motor side effects in schizophrenia patients treated with risperidone.

CD94 defines phenotypically and functionally distinct mouse NK cell subsets.

CD94 surface density identifies a functional intermediary between the CD56bright and CD56dim human NK-cell subsets.

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Purification of human NK cell developmental intermediates from lymph nodes and tonsils.

Differential effects of IL-2 and IL-21 on expansion of the CD4+ CD25+ Foxp3+ T regulatory cells with redundant roles in natural killer cell mediated antibody dependent cellular cytotoxicity in chronic lymphocytic leukemia.

In vivo role of Flt3 ligand and dendritic cells in NK cell homeostasis.

miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Handwriting movement kinematics for quantifying extrapyramidal side effects in patients treated with atypical antipsychotics.

Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia.

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody.

Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue.

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Immature NK cells, capable of producing IL-22, are present in human uterine mucosa.

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

PRDM1/Blimp-1 controls effector cytokine production in human NK cells.

The dynamic character of disguise behavior for text-based, mixed, and stylized signatures.

Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells.

Innate or adaptive immunity? The example of natural killer cells.

IκBζ augments IL-12- and IL-18-mediated IFN-γ production in human NK cells.

A sheep in wolf's clothing.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human.

The large zinc finger protein ZAS3 is a critical modulator of osteoclastogenesis.

Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1 (WT1) single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

LyGDI, a novel SHIP-interacting protein, is a negative regulator of FcγR-mediated phagocytosis.

Associations between spontaneous movement abnormalities and psychotic-like experiences in the general population.

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.

Voxel-based morphometry of patients with schizophrenia or bipolar I disorder: a matched control study.

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect.

ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Targeted immunotherapy for acute myeloid leukemia.

Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.

Extracellular matrix protein CCN1 limits oncolytic efficacy in glioma.

Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.

Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer Cells.

The HDAC inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells with inhibition of STAT5/T-BET signaling and IFNγ generation.

Evidence for a stepwise program of extrathymic T cell development within the human tonsil.

MiR-155 regulates IFN-γ production in natural killer cells.

Regulation of acute graft-versus-host disease by microRNA-155.

miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia.

Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia.

Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias.

Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia.

Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells.

MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response.

RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.

Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia.

Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver.

Quantitative assessment of motor abnormalities in untreated patients with major depressive disorder.

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.

Nonadherence to the isochrony principle in forged signatures.

Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.

Aberrant Overexpression of IL-15 Initiates Large Granular Lymphocyte Leukemia through Chromosomal Instability and DNA Hypermethylation.

inv(16)/t(16;16) acute myeloid leukemia with non-type A CBFB-MYH11 fusions associate with distinct clinical and genetic features and lack KIT mutations.

NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.

Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.

Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target.

Identification of a 24-gene prognostic signature that improves the European LeukemiaNet risk classification of acute myeloid leukemia: an international collaborative study.

Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties.

Overexpression of miR-155 causes expansion, arrest in terminal differentiation and functional activation of mouse natural killer cells.

Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.

Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.

MicroRNAs activate natural killer cells through Toll-like receptor signaling.

Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.

Axl/Gas6 pathway positively regulates FLT3 activation in human natural killer cell development.

Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy.

In rare acute myeloid leukemia patients harboring both RUNX1 and NPM1 mutations, RUNX1 mutations are unusual in structure and present in the germline.

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study.

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Location and cellular stages of natural killer cell development.

Eradicating acute myeloid leukemia in a MllPTD/wt:Flt3ITD/wt murine model: a path to novel therapeutic approaches for human disease.